Last reviewed · How we verify
NCT05089851
Investigation of the Efficacy and Tolerability of a Cosmetic Product With Onabotulinumtoxin A in the Treatment of Facial Lines
NA trial testing Onabotulinumtoxin A in Wrinkles in 29 participants. Completed in 3 June 2021.
3 June 2021
Quick facts
| Lead sponsor | Revision Skincare |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | other |
| Enrollment | 29 |
| Start date | 23 August 2020 |
| Primary completion | 3 June 2021 |
| Estimated completion | 3 June 2021 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- Onabotulinumtoxin A — full drug profile →
- Facial Cleanser
- Facial Moisturizer
- Sunscreen — full drug profile →
Conditions studied
- Wrinkles — all drugs for Wrinkles →
- Photoaging — all drugs for Photoaging →
- Fine Lines — all drugs for Fine Lines →
Sponsor
Revision Skincare — full company profile →
Who can join
Adults 35 to 60, female only, with Wrinkles or Photoaging. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This randomized, multi-center, double-blinded, placebo-controlled, split-face clinical trial was conducted to evaluate the procedure-pairing of OnabotulinumtoxinA with a peptide anti-aging serum to improve facial lines and wrinkles, as well as overall skin texture and radiance of the face after 12 weeks of twice-daily use in female subjects ages 35 - 60 as compared to placebo. A total of 29 subjects completed study participation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05089851
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Wrinkles
Currently open trials in the same condition.
- NCT07495865 — Post-market Clinical Follow-up (PMCF) Study of Safety and Performance of 502-01 AnGelHA 2 · recruiting
- NCT07111156 — A Clinical Study to Test the Safety and Effectiveness of Pinorox® for Improving Visible Signs of Facial Aging Such as Wr · NA · active not recruiting
- NCT06724510 — Safety and Efficacy Evaluation of High Intensity Focused Ultrasound Device in Eyebrow Lifting · NA · recruiting
Other Revision Skincare trials
Trials by the same sponsor.
- NCT07468175 — A 16-week Clinical Study Investigating a Dark Spot Corrector Serum in Women With Moderate Discrete Hyperpigmentation · NA · completed
- NCT07501000 — Evaluation of the Safety and Tolerability of a Brightening Treatment Paired With a Skincare Regimen · NA · completed
- NCT07500623 — Efficacy and Tolerability of a Scalp Serum · NA · completed
- NCT06366503 — Evaluating Procedure Pairing of a Post-Procedure Cream Versus a Comparator in Patients Treated With Fractional Ablative · NA · completed
- NCT06633731 — Clinical Case Study Evaluating the Efficacy and Tolerability of a Topical Facial Treatment on Healthy Females with Fitzp · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05089851 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Revision Skincare
- Last refreshed: 28 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05089851.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing